XML 22 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cashflows provided by operating activities:      
Net Loss of ZimVie Inc. $ (25,825) $ (393,282) $ (63,881)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 34,312 121,686 122,789
Share-based compensation 16,592 27,020 30,289
Deferred income tax provision (4,243) (17,088) (70,422)
Loss on disposal of fixed assets 5,518 2,996 3,358
Other non-cash items 4,985 3,245 1,172
Gain on sale of spine disposal group (Note 3) (11,079) 0 0
Adjustment of spine disposal group to fair value (Note 3) [1] (11,143) 289,456 0
Changes in operating assets and liabilities, net of acquired assets and liabilities      
Income taxes 3,253 (15,054) 5,485
Accounts receivable (4,202) 21,083 (26,156)
Related party receivables 0 8,483 (8,483)
Inventories 6,443 25,446 10,210
Prepaid expenses and other current assets (3,015) 5,340 (19,951)
Accounts payable and accrued liabilities 8,323 (24,759) 21,842
Related party payable 0 (13,176) 13,176
Other assets and liabilities (5,745) (4,248) 5,200
Net cash provided by operating activities 14,174 37,148 24,628
Cash flows provided by (used in) investing activities      
Additions to instruments (1,330) (5,978) (10,089)
Additions to other property, plant and equipment (5,352) (6,509) (16,457)
Net cash proceeds from sale of spine disposal group 290,918 0 0
Other investing activities (1,940) (2,687) (2,117)
Net cash provided by (used in) investing activities 282,296 (15,174) (28,663)
Cash flows used in financing activities      
Net transactions with Zimmer Biomet 0 0 6,920
Dividend paid to Zimmer Biomet 0 0 (540,567)
Proceeds from debt 0 4,760 595,000
Payments on debt (290,000) (29,304) (58,544)
Debt issuance costs 0 0 (5,170)
Payments related to tax withholding for share-based compensation (2,825) (3,402) 0
Proceeds from stock option activity 1,872 2,280 1,059
Business combination contingent consideration payments (3,712) 0 0
Other financing activities 0 0 (5)
Net cash used in financing activities (294,665) (25,666) (1,307)
Effect of exchange rates on cash and cash equivalents (13,001) 1,859 (5,456)
Decrease in cash and cash equivalents (11,196) (1,833) (10,798)
Cash and cash equivalents, beginning of year 87,768 89,601 100,399
Cash and cash equivalents, end of period 76,572 87,768 89,601
Supplemental cash flow information:      
Income taxes paid, net 8,691 20,152 25,730
Interest paid 21,753 37,709 17,283
Promissory note receivable issued in connection with the sale of spine disposal group 60,000 0 0
Interest received in-kind 4,643 0 0
Recognition (derecognition) of right-of-use assets 3,689,000 (1,222,000) (14,174,000)
(Recognition) derecognition of lease liabilities $ (3,692,000) $ 1,225,000 $ 15,303,000
[1] We performed an impairment analysis of the spine segment in December 2023 on a held-for-sale basis. The fair value of consideration to be received upon closure of the transaction was less than the carrying value of the spine segment's net assets, resulting in a write-down of $289.5 million. We updated our analysis as of March 31, 2024, immediately prior to the sale, which resulted in a reduction of the December 2023 write-down of $11.1 million.